Outlook Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Outlook Therapeutics is Russ Trenary, benoemd in Jul2021, heeft een ambtstermijn van 3.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.76M, bestaande uit 34.1% salaris en 65.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.012% van de aandelen van het bedrijf, ter waarde $ 13.81K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 5.4 jaar.

Belangrijke informatie

Russ Trenary

Algemeen directeur

US$1.8m

Totale compensatie

Percentage CEO-salaris	34.1%
Dienstverband CEO	3.3yrs
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	5.4yrs

Recente managementupdates

Recent updates

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Nov 03

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Aug 30

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Aug 10

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Jul 06

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Jul 05

Analyse CEO-vergoeding

Hoe is Russ Trenary's beloning veranderd ten opzichte van Outlook Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$94m
Mar 31 2024	n/a	n/a	-US$159m
Dec 31 2023	n/a	n/a	-US$51m
Sep 30 2023	US$2m	US$600k	-US$59m
Jun 30 2023	n/a	n/a	-US$60m
Mar 31 2023	n/a	n/a	-US$57m
Dec 31 2022	n/a	n/a	-US$70m
Sep 30 2022	US$1m	US$600k	-US$66m
Jun 30 2022	n/a	n/a	-US$65m
Mar 31 2022	n/a	n/a	-US$60m
Dec 31 2021	n/a	n/a	-US$53m
Sep 30 2021	US$8m	US$145k	-US$53m

Compensatie versus markt: De totale vergoeding ($USD 1.76M ) Russ } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.63K ).

Compensatie versus inkomsten: De vergoeding van Russ is gestegen terwijl het bedrijf verliesgevend is.

CEO

Russ Trenary (66 yo)

3.3yrs

Tenure

US$1,758,862

Compensatie

Mr. C. Russell Trenary, III, also known as Russ, serves as a President, Chief Executive Officer and Director at Outlook Therapeutics, Inc., since July 06, 2021. He served as the Chief Executive Officer and...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ralph Thurman	Independent Executive Chairman	6.6yrs	US$242.50k	0.0025% $ 3.0k
C. Trenary	President	3.3yrs	US$1.76m	0.012% $ 13.8k
Lawrence Kenyon	Executive VP	9.2yrs	geen gegevens	0.025% $ 29.9k
Jeffrey Evanson	Chief Commercial Officer	6yrs	US$718.20k	0.16% $ 187.6k
Joel Prieve	Senior Vice President of Licensing and M&A	2.8yrs	geen gegevens	geen gegevens
Surendra Sharma	Senior Vice President of Medical Affairs	1.8yrs	geen gegevens	geen gegevens
Jennifer Kissner	Senior Vice President of Clinical Development & Regulatory Affairs	no data	geen gegevens	geen gegevens
Jedd Comiskey	Senior VP - Head of Europe	less than a year	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van OTLK wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ralph Thurman	Independent Executive Chairman	6.6yrs	US$242.50k	0.0025% $ 3.0k
C. Trenary	President	3.3yrs	US$1.76m	0.012% $ 13.8k
Lawrence Kenyon	Executive VP	6.3yrs	geen gegevens	0.025% $ 29.9k
Kurt Hilzinger	Independent Director	8.9yrs	US$95.00k	0.10% $ 119.0k
Julia Haller	Independent Director	2.3yrs	US$79.00k	0% $ 0
Julian Gangolli	Independent Non-Employee Director	4.6yrs	US$112.50k	0% $ 0
Arun Pillai	Board Observer	no data	geen gegevens	geen gegevens
Gerd Auffarth	Independent Non-Employee Director	4.6yrs	US$79.00k	0% $ 0
Faisal Sukhtian	Independent Director	7.2yrs	US$113.00k	0.014% $ 17.1k
Yezan Haddadin	Independent Director	7.1yrs	US$110.00k	0.013% $ 15.9k
Andong Huang	Independent Director	4.4yrs	US$75.00k	0% $ 0

5.4yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van OTLK wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).

Outlook Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

High number of new directors

Chief Commercial Officer recently sold US$204k worth of stock

Recent updates

Forecast to breakeven in 2027

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

New major risk - Financial position

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Insufficient new directors

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Price target decreased by 13% to US$38.50

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

New major risk - Share price stability

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

Price target decreased by 11% to US$2.01

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Consensus revenue estimates decrease by 92%, EPS upgraded

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates decrease by 33%

Price target decreased by 61% to US$2.63

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

Consensus EPS estimates fall by 12%

New major risk - Negative shareholders equity

Consensus EPS estimates upgraded to US$0.21 loss

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Price target decreased by 7.3% to US$6.13

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2025

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

Price target decreased by 9.5% to US$6.33

High number of new directors

Chief Commercial Officer recently sold US$204k worth of stock

Outlook Therapeutics, Inc. Announces Executive Appointments

Consensus forecasts updated

Forecast breakeven date moved forward to 2024

Outlook Therapeutics, Inc. announced that it expects to receive $30 million in funding from Streeterville Capital, LLC

Outlook Therapeutics, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Forecast breakeven date pushed back to 2025

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Outlook Therapeutics, Inc. Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Independent Director recently bought US$111k worth of stock

Price target increased to US$7.25

No longer forecast to breakeven

Outlook Therapeutics, Inc Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Price target decreased to US$6.33

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Outlook Therapeutics, Inc. Confirms Status of Biologics License Application Submission for ONS-5010

Outlook Therapeutics: A One-Buck Lottery Ticket

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as A Treatment for Wet AMD

Price target decreased to US$6.58

Outlook Therapeutics, Inc Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt Sensibly?

Outlook Therapeutics, Inc. Appoints Alicia Tozier as Senior Vice President of Marketing and Market Access

Independent Director recently bought US$257k worth of stock

Outlook Therapeutics, Inc. Announces Appointment of Joel Prieve as Senior Vice President, Commercial Operations